Welcome to our dedicated page for Iovance Biotherapeutics news (Ticker: $IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iovance Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iovance Biotherapeutics's position in the market.
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the pricing of an underwritten offering of 23,014,000 shares of its common stock at $9.15 per share, aiming to raise approximately $211 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for new employees. The options cover 40,450 shares with an exercise price of $9.87 per share, vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces FDA approval for novel polyclonal TIL therapies for cancer patients. The company will host a conference call and live webcast to discuss the approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (IOVA) receives FDA approval for AMTAGVI, a groundbreaking T cell therapy for advanced melanoma. AMTAGVI is the first individualized T cell therapy for solid tumor cancer, offering hope to patients with limited treatment options. The therapy deploys patient-specific TIL cells to fight cancer, achieving deep and durable responses in clinical trials. The approval is based on safety and efficacy results from the C-144-01 trial, with 31.5% of patients achieving an objective response. AMTAGVI is manufactured at the Iovance Cell Therapy Center in Philadelphia and must be administered in Authorized Treatment Centers (ATCs). Iovance is dedicated to providing access to AMTAGVI for patients with advanced melanoma through a comprehensive support program, IovanceCares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for six new non-executive employees, covering 51,375 shares of common stock. The options were granted under the 2021 Inducement Plan, with an exercise price of $7.94 and vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC). The FDA placed a clinical hold on the IOV-LUN-202 trial due to a recently reported Grade 5 serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. This has no impact on other Iovance clinical trials and is independent of the FDA’s Priority Review of the biologics license application (BLA) for lifileucel in advanced melanoma. Preliminary data for IOV-LUN-202 was reported in July 2023, showing ongoing responses and duration of response greater than six months for 71% of the confirmed responders in the trial. The BLA remains on track toward the PDUFA action date of February 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.67%
Tags
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) granted 44,175 inducement stock options to four new non-executive employees. Each option has an exercise price of $7.89 and vests over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced the approval of inducement stock options for new non-executive employees. The options cover 59,950 shares, with an exercise price of $4.40 and vesting over a three-year period. The awards were granted under Iovance’s 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reports FDA Priority Review of Biologics License Application (BLA) for lifileucel in advanced melanoma on track for PDUFA date of February 24, 2023. Positive regulatory feedback supports lifileucel regulatory submissions in Europe and Canada in 2024. Onboarding completed at approximately 30 Authorized Treatment Centers (ATCs) in preparation for potential U.S. commercial launch of lifileucel as first approved TIL therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
Rhea-AI Summary
Iovance Biotherapeutics, Inc. will report its Q3 and year-to-date 2023 financial results on November 7, 2023. The company focuses on developing novel polyclonal tumor infiltrating lymphocyte therapies for cancer patients. A conference call and live audio webcast will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. The webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
Iovance Biotherapeutics, Inc.
Nasdaq:IOVA
IOVA Rankings
IOVA Stock Data
3.81B
210.92M
0.56%
89.18%
16.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SAN CARLOS
About IOVA
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical